NUVL
Nuvalent, Inc.$123.96+0.00 (—)Prev Close$123.94·MCap$9.11B·P/E—·Vol—·Yield—
▲
Buys (12M)
0
$0.00
▼
Sells (12M)
59
$120.48M
◆
Net Activity
Net Seller
$120.48M
●
Active Insiders
8
last 12 mo
Over the past 12 months, insider activity at Nuvalent, Inc. (NUVL) has been exclusively selling, with 0 insider purchases totaling $0.00 and 59 insider sales totaling $120.48M. The most recent insider transaction was by Pelish Henry E. (officer: Chief Scientific Officer), who sold $261.4K worth of shares on Jul 10, 2026. Nuvalent, Inc. operates in the Healthcare sector, within the Biotechnology industry, with a market cap of $9.11B.
NUVL Insider Trading Activity
| Date | Insider | Role | Type | Shares | Avg Price | Value | Shares After |
|---|---|---|---|---|---|---|---|
| Jul 10, 2026 | Pelish Henry E. | officer: Chief Scientific Officer | Sell | 2,111 | $123.81 | $261.4K | 63,493 |
| Jul 8, 2026 | Porter James Richard | director, officer: President and CEO | Sell | 30,000 | $123.72 | $3.71M | 324,879 |
| Jul 6, 2026 | Noci Darlene | officer: Chief Development Officer | Sell | 23,000 | $123.59 | $2.84M | 58,117-28% |
| Jul 6, 2026 | Balcom Alexandra | officer: Chief Financial Officer | Sell | 11,430 | $123.58 | $1.41M | 85,533 |
| Jul 1, 2026 | Noci Darlene | officer: Chief Development Officer | Sell | 5,500 | $123.51 | $679.3K | 58,117 |
| Jun 11, 2026 | Noci Darlene | officer: Chief Development Officer | Sell | 20,000 | $122.81 | $2.46M | 58,117-26% |
| Jun 10, 2026 | Porter James Richard | director, officer: President and CEO | Sell | 30,000 | $88.53 | $2.66M | 342,384 |
| Jun 1, 2026 | Noci Darlene | officer: Chief Development Officer | Sell | 5,500 | $107.80 | $592.9K | 62,317 |
| Jun 1, 2026 | Miller Deborah Ann | officer: Chief Legal Officer | Sell | 5,500 | $107.84 | $593.1K | 63,733 |
| May 6, 2026 | Porter James Richard | director, officer: President and CEO | Sell | 30,000 | $101.69 | $3.05M | 353,180 |
| May 5, 2026 | Balcom Alexandra | officer: Chief Financial Officer | Sell | 11,430 | $99.00 | $1.13M | 93,091 |
| May 1, 2026 | Noci Darlene | officer: Chief Development Officer | Sell | 5,500 | $99.55 | $547.5K | 59,117 |
| May 1, 2026 | Miller Deborah Ann | officer: Chief Legal Officer | Sell | 5,500 | $99.22 | $545.7K | 60,716 |
| Apr 13, 2026 | Pelish Henry E. | officer: Chief Scientific Officer | Sell | 3,093 | $104.48 | $323.2K | 66,504 |
| Apr 8, 2026 | Porter James Richard | director, officer: President and CEO | Sell | 30,000 | $103.77 | $3.11M | 343,525 |
| Apr 1, 2026 | Noci Darlene | officer: Chief Development Officer | Sell | 5,500 | $97.81 | $537.9K | 61,085 |
| Mar 30, 2026 | Miller Deborah Ann | officer: Chief Legal Officer | Sell | 5,500 | $98.73 | $543.0K | 64,194 |
| Mar 26, 2026 | Balcom Alexandra | officer: Chief Financial Officer | Sell | 25,130 | $98.15 | $2.47M | 108,064 |
| Mar 16, 2026 | Pelish Henry E. | officer: Chief Scientific Officer | Sell | 35,104 | $98.08 | $3.44M | 76,519-31% |
| Mar 10, 2026 | Porter James Richard | director, officer: President and CEO | Sell | 30,000 | $98.99 | $2.97M | 341,294 |
| Mar 2, 2026 | Miller Deborah Ann | officer: Chief Legal Officer | Sell | 5,500 | $103.05 | $566.8K | 62,436 |
| Mar 2, 2026 | Noci Darlene | officer: Chief Development Officer | Sell | 5,500 | $103.03 | $566.7K | 60,617 |
| Jan 29, 2026 | Noci Darlene | Chief Development Officer | Sell | 5,500 | $102.08 | $561.4K | 0 |
| Jan 21, 2026 | Miller Deborah Ann | Chief Legal Officer | Sell | 15,000 | $110.15 | $1.65M | 0 |
| Jan 7, 2026 | Balcom Alexandra | officer: Chief Financial Officer | Sell | 7,417 | $97.25 | $721.3K | 88,279 |
| Jan 7, 2026 | Turner Christopher Durant | officer: Chief Medical Officer | Sell | 7,417 | $97.25 | $721.3K | 61,676 |
| Jan 5, 2026 | Miller Deborah Ann | Chief Legal Officer | Sell | 6,952 | $97.26 | $676.2K | 0 |
| Jan 5, 2026 | Noci Darlene | Chief Development Officer | Sell | 7,417 | $97.25 | $721.3K | 0 |
| Jan 5, 2026 | Pelish Henry E. | Chief Scientific Officer | Sell | 5,160 | $97.24 | $501.8K | 0 |
| Jan 5, 2026 | Porter James Richard | President and CEO | Sell | 27,433 | $97.26 | $2.67M | 0 |
| Jan 2, 2026 | Miller Deborah Ann | Chief Legal Officer | Sell | 10,000 | $100.51 | $1.01M | 0 |
| Dec 30, 2025 | Noci Darlene | Chief Development Officer | Sell | 4,000 | $100.04 | $400.2K | 0 |
| Dec 8, 2025 | Balcom Alexandra | Chief Financial Officer | Sell | 7,084 | $110.32 | $781.5K | 0 |
| Nov 28, 2025 | Noci Darlene | Chief Development Officer | Sell | 4,000 | $108.58 | $434.3K | 0 |
| Nov 24, 2025 | Flynn James E | Director | Sell | 371,287 | $95.45 | $35.44M0.5% OS | 0 |
| Nov 24, 2025 | Shair Matthew | Director | Sell | 7,500 | $109.37 | $820.3K | 0 |
| Nov 17, 2025 | Balcom Alexandra | Chief Financial Officer | Sell | 20,729 | $99.62 | $2.07M | 0 |
| Nov 17, 2025 | Miller Deborah Ann | Chief Legal Officer | Sell | 24,200 | $105.50 | $2.55M | 0 |
| Oct 30, 2025 | Miller Deborah Ann | Chief Legal Officer | Sell | 21,800 | $103.16 | $2.25M | 0 |
| Oct 30, 2025 | Noci Darlene | Chief Development Officer | Sell | 4,000 | $102.92 | $411.7K | 0 |
| Oct 27, 2025 | Shair Matthew | Director | Sell | 60,000 | $100.26 | $6.02M | 0 |
| Oct 20, 2025 | Miller Deborah Ann | Chief Legal Officer | Sell | 5,000 | $94.91 | $474.6K | 0 |
| Oct 16, 2025 | Porter James Richard | President and CEO | Sell | 27,000 | $90.63 | $2.45M | 0 |
| Oct 15, 2025 | Balcom Alexandra | Chief Financial Officer | Sell | 1,683 | $85.57 | $144.0K | 0 |
| Oct 15, 2025 | Miller Deborah Ann | Chief Legal Officer | Sell | 28,000 | $90.72 | $2.54M | 0 |
| Oct 15, 2025 | Pelish Henry E. | Chief Scientific Officer | Sell | 14,205 | $90.04 | $1.28M | 0 |
| Oct 13, 2025 | Balcom Alexandra | Chief Financial Officer | Sell | 40,000 | $87.36 | $3.49M | 0 |
| Oct 13, 2025 | Pelish Henry E. | Chief Scientific Officer | Sell | 10,070 | $88.84 | $894.6K | 0 |
| Oct 1, 2025 | Balcom Alexandra | Chief Financial Officer | Sell | 20,000 | $85.48 | $1.71M | 0 |
| Sep 29, 2025 | Balcom Alexandra | Chief Financial Officer | Sell | 27,588 | $85.05 | $2.35M | 0 |
Showing 1–50 of 195
1 / 4
NUVL Insider Buying Activity
The following table shows recent insider purchases of Nuvalent, Inc. (NUVL) stock reported via SEC Form 4 filings.
No insider buying activity found for NUVL in the last 12 months.
NUVL Insider Selling Activity
The following table shows recent insider sales of Nuvalent, Inc. (NUVL) stock reported via SEC Form 4 filings.
| Date | Insider | Role | Type | Shares | Avg Price | Value | Shares After |
|---|---|---|---|---|---|---|---|
| Jul 10, 2026 | Pelish Henry E. | officer: Chief Scientific Officer | Sell | 2,111 | $123.81 | $261.4K | 63,493 |
| Jul 8, 2026 | Porter James Richard | director, officer: President and CEO | Sell | 30,000 | $123.72 | $3.71M | 324,879 |
| Jul 6, 2026 | Noci Darlene | officer: Chief Development Officer | Sell | 23,000 | $123.59 | $2.84M | 58,117-28% |
| Jul 6, 2026 | Balcom Alexandra | officer: Chief Financial Officer | Sell | 11,430 | $123.58 | $1.41M | 85,533 |
| Jul 1, 2026 | Noci Darlene | officer: Chief Development Officer | Sell | 5,500 | $123.51 | $679.3K | 58,117 |
| Jun 11, 2026 | Noci Darlene | officer: Chief Development Officer | Sell | 20,000 | $122.81 | $2.46M | 58,117-26% |
| Jun 10, 2026 | Porter James Richard | director, officer: President and CEO | Sell | 30,000 | $88.53 | $2.66M | 342,384 |
| Jun 1, 2026 | Noci Darlene | officer: Chief Development Officer | Sell | 5,500 | $107.80 | $592.9K | 62,317 |
| Jun 1, 2026 | Miller Deborah Ann | officer: Chief Legal Officer | Sell | 5,500 | $107.84 | $593.1K | 63,733 |
| May 6, 2026 | Porter James Richard | director, officer: President and CEO | Sell | 30,000 | $101.69 | $3.05M | 353,180 |
| May 5, 2026 | Balcom Alexandra | officer: Chief Financial Officer | Sell | 11,430 | $99.00 | $1.13M | 93,091 |
| May 1, 2026 | Noci Darlene | officer: Chief Development Officer | Sell | 5,500 | $99.55 | $547.5K | 59,117 |
| May 1, 2026 | Miller Deborah Ann | officer: Chief Legal Officer | Sell | 5,500 | $99.22 | $545.7K | 60,716 |
| Apr 13, 2026 | Pelish Henry E. | officer: Chief Scientific Officer | Sell | 3,093 | $104.48 | $323.2K | 66,504 |
| Apr 8, 2026 | Porter James Richard | director, officer: President and CEO | Sell | 30,000 | $103.77 | $3.11M | 343,525 |
| Apr 1, 2026 | Noci Darlene | officer: Chief Development Officer | Sell | 5,500 | $97.81 | $537.9K | 61,085 |
| Mar 30, 2026 | Miller Deborah Ann | officer: Chief Legal Officer | Sell | 5,500 | $98.73 | $543.0K | 64,194 |
| Mar 26, 2026 | Balcom Alexandra | officer: Chief Financial Officer | Sell | 25,130 | $98.15 | $2.47M | 108,064 |
| Mar 16, 2026 | Pelish Henry E. | officer: Chief Scientific Officer | Sell | 35,104 | $98.08 | $3.44M | 76,519-31% |
| Mar 10, 2026 | Porter James Richard | director, officer: President and CEO | Sell | 30,000 | $98.99 | $2.97M | 341,294 |
| Mar 2, 2026 | Miller Deborah Ann | officer: Chief Legal Officer | Sell | 5,500 | $103.05 | $566.8K | 62,436 |
| Mar 2, 2026 | Noci Darlene | officer: Chief Development Officer | Sell | 5,500 | $103.03 | $566.7K | 60,617 |
| Jan 29, 2026 | Noci Darlene | Chief Development Officer | Sell | 5,500 | $102.08 | $561.4K | 0 |
| Jan 21, 2026 | Miller Deborah Ann | Chief Legal Officer | Sell | 15,000 | $110.15 | $1.65M | 0 |
| Jan 7, 2026 | Balcom Alexandra | officer: Chief Financial Officer | Sell | 7,417 | $97.25 | $721.3K | 88,279 |
| Jan 7, 2026 | Turner Christopher Durant | officer: Chief Medical Officer | Sell | 7,417 | $97.25 | $721.3K | 61,676 |
| Jan 5, 2026 | Miller Deborah Ann | Chief Legal Officer | Sell | 6,952 | $97.26 | $676.2K | 0 |
| Jan 5, 2026 | Noci Darlene | Chief Development Officer | Sell | 7,417 | $97.25 | $721.3K | 0 |
| Jan 5, 2026 | Pelish Henry E. | Chief Scientific Officer | Sell | 5,160 | $97.24 | $501.8K | 0 |
| Jan 5, 2026 | Porter James Richard | President and CEO | Sell | 27,433 | $97.26 | $2.67M | 0 |
| Jan 2, 2026 | Miller Deborah Ann | Chief Legal Officer | Sell | 10,000 | $100.51 | $1.01M | 0 |
| Dec 30, 2025 | Noci Darlene | Chief Development Officer | Sell | 4,000 | $100.04 | $400.2K | 0 |
| Dec 8, 2025 | Balcom Alexandra | Chief Financial Officer | Sell | 7,084 | $110.32 | $781.5K | 0 |
| Nov 28, 2025 | Noci Darlene | Chief Development Officer | Sell | 4,000 | $108.58 | $434.3K | 0 |
| Nov 24, 2025 | Flynn James E | Director | Sell | 371,287 | $95.45 | $35.44M0.5% OS | 0 |
| Nov 24, 2025 | Shair Matthew | Director | Sell | 7,500 | $109.37 | $820.3K | 0 |
| Nov 17, 2025 | Balcom Alexandra | Chief Financial Officer | Sell | 20,729 | $99.62 | $2.07M | 0 |
| Nov 17, 2025 | Miller Deborah Ann | Chief Legal Officer | Sell | 24,200 | $105.50 | $2.55M | 0 |
| Oct 30, 2025 | Miller Deborah Ann | Chief Legal Officer | Sell | 21,800 | $103.16 | $2.25M | 0 |
| Oct 30, 2025 | Noci Darlene | Chief Development Officer | Sell | 4,000 | $102.92 | $411.7K | 0 |
| Oct 27, 2025 | Shair Matthew | Director | Sell | 60,000 | $100.26 | $6.02M | 0 |
| Oct 20, 2025 | Miller Deborah Ann | Chief Legal Officer | Sell | 5,000 | $94.91 | $474.6K | 0 |
| Oct 16, 2025 | Porter James Richard | President and CEO | Sell | 27,000 | $90.63 | $2.45M | 0 |
| Oct 15, 2025 | Balcom Alexandra | Chief Financial Officer | Sell | 1,683 | $85.57 | $144.0K | 0 |
| Oct 15, 2025 | Miller Deborah Ann | Chief Legal Officer | Sell | 28,000 | $90.72 | $2.54M | 0 |
| Oct 15, 2025 | Pelish Henry E. | Chief Scientific Officer | Sell | 14,205 | $90.04 | $1.28M | 0 |
| Oct 13, 2025 | Balcom Alexandra | Chief Financial Officer | Sell | 40,000 | $87.36 | $3.49M | 0 |
| Oct 13, 2025 | Pelish Henry E. | Chief Scientific Officer | Sell | 10,070 | $88.84 | $894.6K | 0 |
| Oct 1, 2025 | Balcom Alexandra | Chief Financial Officer | Sell | 20,000 | $85.48 | $1.71M | 0 |
| Sep 29, 2025 | Balcom Alexandra | Chief Financial Officer | Sell | 27,588 | $85.05 | $2.35M | 0 |
NUVL Insiders
Similar Stocks to NUVL
VRTX
Vertex Pharmaceuticals Incorporated
$476.29+0.08%
$126.50B
REGN
Regeneron Pharmaceuticals, Inc.
$662.73+1.01%
$68.29B
ALNY
Alnylam Pharmaceuticals, Inc.
$275.93-1.72%
$43.19B
RVMD
Revolution Medicines, Inc.
$185.71+0.42%
$40.34B
MRNA
Moderna, Inc.
$68.11+1.00%
$27.09B
INSM
Insmed Incorporated
$109.25-0.67%
$25.06B
INCY
Incyte Corporation
$114.43-0.30%
$23.32B
UTHR
United Therapeutics Corporation
$530.63+0.75%
$23.22B